The U.S. Food and Drug Administration approved albiglutide for treatment of adult type 2 diabetes a few months ago. It will be sold in the U.S. as Tanzeum. It’s a once-a-week subcutaneous injection.
Albiglutide is a GLP-1 receptor agonist, joining exenatide and liraglutide in that class.
It’s not a first-line drug for diabetes. In clinical studies, it’s been used alone and with metformin, glimiperide (a sulfonylurea), pioglitazone, and insulin.
The most frequent side effects have been upper respiratory infections, diarrhea, nausea, and injection site reactions.
If I had diabetes, I’d be sure to do all I could for my condition with diet and exercise before ramping up the drugs.
Steve Parker, M.D.